Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T7OW
|
|||
| Former ID |
DAP000212
|
|||
| Drug Name |
Dopamine
|
|||
| Synonyms |
Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Approved | [1], [2] | |
| Hypotension [ICD-11: BA20-BA21] | Phase 1 | [1], [3] | ||
| Therapeutic Class |
Cardiotonic Agents
|
|||
| Company |
Baxter Healthcare Corp Anesthesia And Critical Care
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H11NO2
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1CCN)O)O
|
|||
| InChI |
1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
|
|||
| InChIKey |
VYFYYTLLBUKUHU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51-61-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6517, 444583, 794678, 840958, 841083, 3133522, 4396596, 7888623, 7979122, 8026221, 8145174, 8150742, 11111282, 11335955, 11361194, 11363906, 11364800, 11364894, 11366468, 11367362, 11367456, 11369030, 11369924, 11370018, 11371252, 11372964, 11373057, 11374268, 11375524, 11375618, 11377192, 11378091, 11378187, 11462166, 11484941, 11488839, 11490222, 11492340, 11494826, 11534314, 15170929, 24439043, 26612791, 26719173, 26750067, 26753786, 26753787, 37024415, 46506043, 47213204
|
|||
| ChEBI ID |
CHEBI:18243
|
|||
| ADReCS Drug ID | BADD_D00708 ; BADD_D00709 | |||
| SuperDrug ATC ID |
C01CA04
|
|||
| SuperDrug CAS ID |
cas=000051616
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 940). | |||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. | |||
| REF 5 | Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet. 2007Sep 5;144B(6):809-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.